Autolus Therapeutics (AUTL)
AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Autolus Therapeutics Statistics
Share Statistics
Autolus Therapeutics has 266.12M shares outstanding. The number of shares has increased by 0.07% in one year.
Shares Outstanding | 266.12M |
Shares Change (YoY) | n/a |
Shares Change (QoQ) | 0.03% |
Owned by Institutions (%) | n/a |
Shares Floating | 236.67M |
Failed to Deliver (FTD) Shares | 1.92K |
FTD / Avg. Volume | 0.1% |
Short Selling Information
The latest short interest is 7.68M, so 2.89% of the outstanding shares have been sold short.
Short Interest | 7.68M |
Short % of Shares Out | 2.89% |
Short % of Float | 3.25% |
Short Ratio (days to cover) | 3.88 |
Valuation Ratios
The PE ratio is -5.38 and the forward PE ratio is -4.56.
PE Ratio | -5.38 |
Forward PE | -4.56 |
PS Ratio | 659.71 |
Forward PS | 3.8 |
PB Ratio | 10.05 |
P/FCF Ratio | -7.15 |
PEG Ratio | n/a |
Enterprise Valuation
Autolus Therapeutics has an Enterprise Value (EV) of 933.59M.
EV / Earnings | -4.48 |
EV / Sales | 549.82 |
EV / EBITDA | -5.96 |
EV / EBIT | -4.79 |
EV / FCF | -5.96 |
Financial Position
The company has a current ratio of 6.15, with a Debt / Equity ratio of 0.48.
Current Ratio | 6.15 |
Quick Ratio | 6.15 |
Debt / Equity | 0.48 |
Total Debt / Capitalization | 32.21 |
Cash Flow / Debt | -2.75 |
Interest Coverage | -4.33 |
Financial Efficiency
Return on equity (ROE) is -1.87% and return on capital (ROIC) is -118.59%.
Return on Equity (ROE) | -1.87% |
Return on Assets (ROA) | -0.56% |
Return on Capital (ROIC) | -118.59% |
Revenue Per Employee | 3.67K |
Profits Per Employee | -450.07K |
Employee Count | 463 |
Asset Turnover | 0 |
Inventory Turnover | 0 |
Taxes
Income Tax | -19.00K |
Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -63.5% in the last 52 weeks. The beta is 2.04, so Autolus Therapeutics's price volatility has been higher than the market average.
Beta | 2.04 |
52-Week Price Change | -63.5% |
50-Day Moving Average | 2.79 |
200-Day Moving Average | 3.79 |
Relative Strength Index (RSI) | 38.18 |
Average Volume (20 Days) | 1.90M |
Income Statement
In the last 12 months, Autolus Therapeutics had revenue of 1.70M and earned -208.38M in profits. Earnings per share was -1.2.
Revenue | 1.70M |
Gross Profit | -4.87M |
Operating Income | -195.03M |
Net Income | -208.38M |
EBITDA | -156.77M |
EBIT | -195.03M |
Earnings Per Share (EPS) | -1.2 |
Balance Sheet
The company has 239.57M in cash and 52.97M in debt, giving a net cash position of 186.60M.
Cash & Cash Equivalents | 239.57M |
Total Debt | 52.97M |
Net Cash | 186.60M |
Retained Earnings | -878.56M |
Total Assets | 827.49M |
Working Capital | 665.64M |
Cash Flow
In the last 12 months, operating cash flow was -145.59M and capital expenditures -10.99M, giving a free cash flow of -156.57M.
Operating Cash Flow | -145.59M |
Capital Expenditures | -10.99M |
Free Cash Flow | -156.57M |
FCF Per Share | -0.9 |
Margins
Gross margin is -286.63%, with operating and profit margins of -11.49K% and -12.27K%.
Gross Margin | -286.63% |
Operating Margin | -11.49K% |
Pretax Margin | -12.27K% |
Profit Margin | -12.27K% |
EBITDA Margin | -9.23K% |
EBIT Margin | -11.49K% |
FCF Margin | -9.22K% |
Dividends & Yields
AUTL does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | -53.81% |
FCF Yield | -26.44% |
Analyst Forecast
The average price target for AUTL is $10.5, which is 370.9% higher than the current price. The consensus rating is "Strong Buy".
Price Target | $10.5 |
Price Target Difference | 370.9% |
Analyst Consensus | Strong Buy |
Analyst Count | 4 |
Scores
Altman Z-Score | -0.57 |
Piotroski F-Score | 3 |